GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » H. Lundbeck AS (OTCPK:HLBBF) » Definitions » 3-Year EBITDA Growth Rate

H. Lundbeck AS (H. Lundbeck AS) 3-Year EBITDA Growth Rate : -40.80% (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is H. Lundbeck AS 3-Year EBITDA Growth Rate?

H. Lundbeck AS's EBITDA per Share for the three months ended in Mar. 2024 was $0.19.

During the past 12 months, H. Lundbeck AS's average EBITDA Per Share Growth Rate was 5.20% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was -40.80% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -35.40% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was -3.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of H. Lundbeck AS was 119.10% per year. The lowest was -49.30% per year. And the median was 5.50% per year.

Competitive Comparison of H. Lundbeck AS's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, H. Lundbeck AS's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

H. Lundbeck AS's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, H. Lundbeck AS's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where H. Lundbeck AS's 3-Year EBITDA Growth Rate falls into.


H. Lundbeck AS 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

H. Lundbeck AS  (OTCPK:HLBBF) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

H. Lundbeck AS 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of H. Lundbeck AS's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

H. Lundbeck AS (H. Lundbeck AS) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » H. Lundbeck AS (OTCPK:HLBBF) » Definitions » 3-Year EBITDA Growth Rate
Comparable Companies
OCSE:STENO ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA TSE:4507 VTRS NBIX XSWX:SDZ SZSE:000538 BOM:500124 BOM:532321 TSE:4523 HKSE:03692 BOM:543904 NSE:DIVISLAB NSE:TORNTPHARM CTLT
Traded in Other Exchanges
HLUBF:USA 0ABR:UK 0ND5:UK HLUN A:Denmark HLUN B:Denmark LDBA:Germany
Address
Ottiliavej 9, Valby, DNK, 2500
Website
https://www.lundbeck.com
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system, or CNS, drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.